Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News Lipocine Inc LPCN

Healthcare Biotechnology
Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate. The company’s pipeline candidates also include LPCN 1111 (TLANDO XR), a next-generation... see more

Current News (NDAQ:LPCN)

Lipocine's PPD Phase 3 Study (LPCN 1154) Hits 80% Enrollment Milestone

PR Newswire December 16, 2025

Lipocine Highlights Promising Interim Safety Profile in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD)

PR Newswire November 18, 2025

Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2025

PR Newswire November 6, 2025

Lipocine Presents LPCN 2401 Clinical Data at ObesityWeek®

PR Newswire November 4, 2025

Lipocine Provides Progress Update on LPCN 1154 Phase 3 Clinical Trial in Postpartum Depression (PPD)

PR Newswire September 30, 2025

Lipocine to Present at H.C. Wainwright 27th Annual Global Investment Conference

PR Newswire September 5, 2025

Lipocine Announces LPCN 2101 Abstracts Accepted for Presentation at AES 2025

PR Newswire August 26, 2025

Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2025

PR Newswire August 5, 2025

Lipocine Announces First Patient Dosed in Phase 3 Clinical Trial for LPCN 1154 in Postpartum Depression

PR Newswire June 26, 2025
View More News ››

Opinion & Analysis (NDAQ:LPCN)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:LPCN)

Lipocine Inc. (NASDAQ:LPCN): A Biotech Innovator Leveraging

Looks like LPCN is making some serious moves. FDA approval for TLANDO last year was huge, and now they've got Verity Pharma on board...
MikeTester - January 24, 2025

Next one to go up big time???

https://youtu.be/Q5spPc_DoRA
Khumamayo - January 27, 2021

some catalysts coming up

Should be a good week/next few months with major catalysts coming up. This can be a $3-$4 stock if things fo positive
unclepieman - January 11, 2021

still holding this stock

added more of this one,by using dollar cost averaging for it,so glta shareholders.
coolfooldumbguy - February 24, 2020

added more of this one

using DCA,dollar cost averaging for it as it is one of my loser stocks and it is so cheap glta.
coolfooldumbguy - December 16, 2019

starting its upswing

for shareholders,it looks like it will set new highs from here,so glta.
coolfooldumbguy - March 12, 2019
View more Bullboard ››

TAG Oil Ltd.

TAG Oil Ltd.

TAG Oil Ltd., together with its subsidiaries, engages in the exploration, development, and production of oil and gas in ...
View More »

Podcasts